WO2007147868A3 - Prevention of muscle atrophy - Google Patents
Prevention of muscle atrophy Download PDFInfo
- Publication number
- WO2007147868A3 WO2007147868A3 PCT/EP2007/056181 EP2007056181W WO2007147868A3 WO 2007147868 A3 WO2007147868 A3 WO 2007147868A3 EP 2007056181 W EP2007056181 W EP 2007056181W WO 2007147868 A3 WO2007147868 A3 WO 2007147868A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- muscle atrophy
- prevention
- treating muscle
- relates
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a method of treating muscle atrophy, a pathological condition associated with many diseases. The invention also relates to the use of an agent in the manufacture of a medicament for treating muscle atrophy. There is also provided a method of identifying agents for potential use in treating muscle atrophy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0612273A GB0612273D0 (en) | 2006-06-21 | 2006-06-21 | Prevention of muscle atrophy |
GB0612273.3 | 2006-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007147868A2 WO2007147868A2 (en) | 2007-12-27 |
WO2007147868A3 true WO2007147868A3 (en) | 2008-02-21 |
Family
ID=36803603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/056181 WO2007147868A2 (en) | 2006-06-21 | 2007-06-21 | Prevention of muscle atrophy |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0612273D0 (en) |
WO (1) | WO2007147868A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2100879A1 (en) | 2008-03-13 | 2009-09-16 | 4Sc Ag | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
US20140147434A1 (en) * | 2011-05-06 | 2014-05-29 | Ecole Polytechnique Federale De Lausanne (Epfl) | NCoR1 is a Physiological Modulator of Muscle Mass and Oxidative Function |
DK3071196T3 (en) * | 2013-11-20 | 2019-07-01 | Ohio State Innovation Foundation | HDAC inhibitors for suppression of cancer-associated cachexia |
CA2930606C (en) * | 2013-11-20 | 2022-05-10 | Ohio State Innovation Foundation | Methods for suppressing cancer-related cachexia |
CN106929513A (en) * | 2017-04-07 | 2017-07-07 | 东南大学 | The nano antibody of mRNA codings and its application |
BR112022005595A2 (en) | 2019-09-27 | 2022-07-19 | Takeda Pharmaceuticals Co | COMPOUND, DRUG, METHODS FOR INHIBITING HISTONE DEACETYLASE 6 AND FOR PROPHYLAXIS OR TREATMENT OF ALZHEIMER'S DISEASE OR PROGRESSIVE SUPRANUCLEAR PALSY IN A MAMMAL, AND, COMPOUND USE |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006018657A1 (en) * | 2004-08-18 | 2006-02-23 | University Of East Anglia | Hdac inhibitors and methods of use thereof |
US20060069049A1 (en) * | 2003-12-29 | 2006-03-30 | President And Fellows Of Harvard College | Methods and reagents related to foxo |
-
2006
- 2006-06-21 GB GB0612273A patent/GB0612273D0/en not_active Ceased
-
2007
- 2007-06-21 WO PCT/EP2007/056181 patent/WO2007147868A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060069049A1 (en) * | 2003-12-29 | 2006-03-30 | President And Fellows Of Harvard College | Methods and reagents related to foxo |
WO2006018657A1 (en) * | 2004-08-18 | 2006-02-23 | University Of East Anglia | Hdac inhibitors and methods of use thereof |
Non-Patent Citations (6)
Title |
---|
BLANCHARD F ET AL: "Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 10, no. 3, 1 February 2005 (2005-02-01), pages 197 - 204, XP004748155, ISSN: 1359-6446 * |
GLOZAK ET AL: "Acetylation and deacetylation of non-histone proteins", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER, AMSTERDAM, NL, vol. 363, 19 December 2005 (2005-12-19), pages 15 - 23, XP005186882, ISSN: 0378-1119 * |
HAGGARTY STEPHEN J ET AL: "Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 8, 15 April 2003 (2003-04-15), pages 4389 - 4394, XP002263858, ISSN: 0027-8424 * |
HIRTZ D ET AL: "Challenges and opportunities in clinical trials for spinal muscular atrophy", NEUROLOGY, vol. 65, no. 9, November 2005 (2005-11-01), pages 1352 - 1357, XP002459627, ISSN: 0028-3878 * |
KANDARIAN SUSAN C ET AL: "Intracellular signaling during skeletal muscle atrophy", MUSCLE & NERVE, vol. 33, no. 2, February 2006 (2006-02-01), pages 155 - 165, XP002459626, ISSN: 0148-639X * |
SANDRI MARCO ET AL: "Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy", CELL, vol. 117, no. 3, 30 April 2004 (2004-04-30), pages 399 - 412, ISSN: 0092-8674 * |
Also Published As
Publication number | Publication date |
---|---|
GB0612273D0 (en) | 2006-08-02 |
WO2007147868A2 (en) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277322A (en) | Compositions and methods for treating collagen-mediated diseases | |
WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
WO2007136759A3 (en) | Method for the treatment and prevention of ocular disorders | |
WO2008021210A3 (en) | Methods and compositions for the treatment of neurodegenerative disorders | |
WO2008036765A3 (en) | Micrornas differentially expressed in pancreatic diseases and uses thereof | |
WO2007137071A3 (en) | Compositions of r(+) and s(-) pramipexole and methods of using the same | |
WO2008042231A3 (en) | Compositions and methods for evaluating and treating heart failure | |
WO2010127099A3 (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
MX349787B (en) | Oral dosage forms including an antiplatelet agent and an acid inhibitor. | |
WO2007117971A3 (en) | Ocular allergy treatments | |
WO2006078463A3 (en) | Method for treating cardiovascular disease | |
WO2007022518A8 (en) | New uses of glucoregulatory proteins | |
WO2008016659A3 (en) | Agents for treating neurodegenerative diseases | |
EP2060264A4 (en) | Agent for treating eye diseases | |
EP2139460A4 (en) | Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases | |
WO2007014943A3 (en) | Therapy for neurological diseases | |
WO2007147868A3 (en) | Prevention of muscle atrophy | |
WO2010077339A3 (en) | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | |
WO2007144057A3 (en) | Antimicrobial carbon | |
WO2008067559A3 (en) | Methods for treating and diagnosing fibrotic and fibroproliferative diseases | |
WO2008127279A3 (en) | Methods for treating, preventing and diagnosing porcine ttv infection | |
WO2006088786A3 (en) | Compounds and uses thereof | |
WO2011011706A3 (en) | Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents | |
WO2006078336A3 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
WO2009043858A3 (en) | Methods for treating and diagnosing a cancer secreting cath-d or alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07765531 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07765531 Country of ref document: EP Kind code of ref document: A2 |